A Phase 1 Study Of The Safety, Pharmacokinetics And Anti-tumor Activity Of Talazoparib, Poly (Adp-ribose) Polymerase (Parp) Inhibitor, In Japanese Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Talazoparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Jan 2019 Planned End Date changed from 3 Mar 2019 to 1 Dec 2022.
- 02 Jan 2019 Planned primary completion date changed from 3 Mar 2019 to 1 Jun 2021.
- 12 Dec 2017 Status changed from not yet recruiting to recruiting.